Durable remission of leptomeningeal metastasis of breast cancer with letrozole: A case report and implications of biomarkers on treatment selection

Japanese Journal of Clinical Oncology

Volumn 33, Issue 5, 2003, Pages 229-231

  Ozdogan, Mustafa ^a   Samur, Mustafa ^a   Bozcuk, Hakan S ^a   Sagtas, Ergin ^b   Yildiz, Mustafa ^a   Artac, Mehmet ^a   Savas, Burhan ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

^b Department of Radiology   (Turkey)

Author keywords

Breast cancer; Leptomeningeal carcinomatosis; Letrozole

Indexed keywords

BIOLOGICAL MARKER; CA 15-3 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; NITRILE; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CASE REPORT; EARLY DIAGNOSIS; FEMALE; HUMAN; MENINGEAL METASTASIS; PATIENT SELECTION; PROGNOSIS; SURVIVAL TIME; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BLOOD; BREAST TUMOR; LUNG CARCINOMA; LYMPH NODE METASTASIS; MENINGIOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; REMISSION; SKULL IRRADIATION; SURVIVOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; CRANIAL IRRADIATION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MENINGEAL NEOPLASMS; MIDDLE AGED; NITRILES; REMISSION INDUCTION; SURVIVORS; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 0042700228     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg046     Document Type: Article

References (13)

1. Grossman SA. Advances in the Treatment of Central Nervous System Metastases: Treatment of Leptomeningeal Metastasis. American Society of Clinical Oncology, Education Book, Alexandria, VA. 2001;598-604.
2. Boogerd W, Dorresteijn LD, van Der Sande JJ, de Gast GC, Bruning PF. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000;12:117-9.
3. Chamberlain MC. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2001;13:425-6.
4. Collie DA, Brush JP, Lammie GA, Grant R, Kunkler I, Leonard R, et al. Imaging features of leptomeningeal metastases. Clin Radiol 1999;54:765-71.
5. Chamberlain MC, Kormanik PR. Carcinomatous meningitis secondary to breast cancer: Predictors of response to combined modality therapy. J Neurooncol 1997;35:55-64.
6. Spataro V, Price K, Goldhirsch A, Cavalli F, Simoncini E, Castiglione M, et al. Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 1992;3:733-40.
7. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: Interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125-30.
8. Savas B, Karaveli S, Uslu G, Basaran L. Significance of p53 and cerb-B2 in predicting response to CMF treatment in breast carcinoma. Proc Am Soc Clin Oncol 1999;18: (Abstract 378).
9. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002;20:1467-72.
10. Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocrinol Rev 1990;11:221-65.
11. Brodie AMH. Aromatase, its inhibitors and their use in breast cancer treatment. Pharmacol Ther 1993;60:501-15.
12. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-l6.
13. Wood L, Palmer M, Hewitt J, Urtasun R, Bruera E, Rapp E, et al. Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma. Br J Cancer 1998;77:627-31.